Latest News

View All Recent News »

ILUVIEN® Is Now Widely Available To Diabetic Macular Edema Patients Throughout The U.S.

April 21, 2015 -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now...

Read More »

Alimera Sciences' ILUVIEN® Receives 17th European Marketing Authorization; Completing Second Wave Of Country Approvals

April 14, 2015 -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that marketing authorization has been granted by the...

Read More »

Alimera Sciences to Host Analyst and Investor Luncheon on Wednesday, March 25, 2015 in New York City

March 19, 2015 -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it will host an Analyst and Investor Luncheon on...

Read More »